Neurocrine Biosciences’ Phase 2 SAVITRI study has demonstrated the efficacy of NBI-1065845 in reducing depressive symptoms in adults with major depressive disorder. The study met its primary and key secondary endpoints, with NBI-1065845 showing statistically significant improvement in Montgomery Åsberg Depression Rating Scale (MADRS) total score at both Day 28 and Day 56 compared to placebo. NBI-1065845 was generally well-tolerated, with headache being the most common adverse event.